top of page

Promising U.S. Pharmaceutical Lab Seeking a Strategic Financial Investor

Listing Code:



Not Disclosed


Medical Labs

Asking Price:




Company Overview American HealthCare Capital is pleased to exclusively present a U.S. based, state-of-the-art, FDA-approved, cGMP-certified, full-range laboratory facility seeking a strategic financial investor. The facility’s clients outsource their product formulary development (Pharmaceutical, Nutraceutical, and Cosmetics) via contract analytical testing services. As an affordable but technologically advanced outsourcing solution, the Company enables clients to develop multiple ranges of products including DEA-scheduled drugs (Class I-V and List I Chemicals) quickly and efficiently without the cost or the hassle associated with having an in-house laboratory. Since 2015, Company founders have invested over $1 million in building an ultra-modern, cGMP-certified, and FDA-approved laboratory that meets and exceeds similar laboratories in North America. The following is the list of some of the services offered by the Company: Contract Testing, Product Development, Pharmaceutical Laboratory, Chemical Testing, CRO Pharma, and Environmental Testing. The U.S. pharma lab wants to add a manufacturing facility to its current laboratory to address the market demand for certain drugs, which can only be manufactured in the U.S. for the U.S. market per the latest change in FDA regulations. The new manufacturing facility will cover an area of approximately 50,000 sq. ft., with 20,000 sq. ft. dedicated to production, 10,000 sq. ft. for the warehouse, and the remaining space allocated to R&D, administration offices, canteen, utilities, and engineering rooms. This new manufacturing facility will leverage formulations already owned by the Laboratory, targeting high-value and scarcely available drugs needed in the U.S. market. The leadership Team is also planning to expand the number of formulations and products offered, with a strategy that leverages the unique mix of laboratory certifications, capabilities, and location, by accessing abbreviated FDA-regulated drug approval processes. The Opportunity The founders and the management team of the Company, who have deep expertise in operating all segments of a CRO (Contract-Research-Organization), are seeking a strategic partner and a financial sponsor to help them use their existing laboratory as a stepping stone to expand their product offerings to include manufacturing and transition to becoming a CDMO (Contract Development Manufacturing Organization). The Seller of this FDA-approved U.S. pharma lab is open to all deal structures, including a majority control sale and a roll of equity, as well as an earn-out based on future sales. The asking price of this opportunity is to be determined and excludes cash, accounts receivable, and inventory.

Inquire About This Listing:

In order to learn more about our listing, you must:

1. Complete a Buyer Profile:

This profile will be used to pre-qualify buyers and determine whether we can share additional details about our listings. If you have already completed a Buyer Profile, disregard.


2. Sign NDA with Listing Code:

To learn more about this listing, you must sign an NDA. When completing the NDA, you will need to copy the exact LISTING CODE and LISTING TITLE.

Listing Code:


Listing Title:

Promising U.S. Pharmaceutical Lab Seeking a Strategic Financial Investor

Heading 4

Contact the Team

Jack Eskenazi American Healthcare Capital

Jack Eskenazi


American HealthCare Capital

Dr. Allen Nazeri DDS MBA.jpg

Dr. Allen Nazeri 

Managing Partner

PRIME exits

Join our mailing list to receive our latest news, and listings.

Thanks for submitting!

bottom of page